Clinical trial
A First-In-Human Phase I Study in 3 Parts: Randomized, Double-blind, Placebocontrolled, Sequential Group Investigation of the Safety, Tolerability, Pharmacokinetics of AEF0217 After Oral, Single and Multiple Ascending Doses, and an Open Label, Cross-over Investigation of the Effect of Food on the Bioavailability of AEF0217 in Healthy Volunteers.
NCT05170737 is registered in ClinicalTrials.gov with Aelis Farma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-In-Human Phase I Study in 3 Parts: Randomized, Double-blind, Placebocontrolled, Sequential Group Investigation of the Safety, Tolerability, Pharmacokinetics of AEF0217 After Oral, Single and Multiple Ascending Doses, and an Open Label, Cross-over Investigation of the Effect of Food on the Bioavailability of AEF0217 in Healthy Volunteers.
- Lead sponsor
- Aelis Farma
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 1, 2021
- Completion date
- June 28, 2022
- Enrollment
- 68 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
safety, tolerability, pharmacokinetics of aef0217